CONMED (NYSE:CNMD) Issues FY 2025 Earnings Guidance

CONMED (NYSE:CNMD) updated its FY 2025 earnings guidance on Wednesday. The company provided EPS guidance of 4.250-4.400 for the period, compared to the consensus EPS estimate of 4.740. The company issued revenue guidance of $1.3 billion-$1.4 billion, compared to the consensus revenue estimate of $1.4 billion.

CONMED Stock Down 7.8 %

NYSE CNMD traded down $5.74 during mid-day trading on Thursday, reaching $68.26. The stock had a trading volume of 438,605 shares, compared to its average volume of 415,689. The stock has a market cap of $2.11 billion, a PE ratio of 16.30, a price-to-earnings-growth ratio of 1.04 and a beta of 1.46. The company has a debt-to-equity ratio of 1.01, a current ratio of 2.27 and a quick ratio of 1.06. The company has a fifty day moving average price of $70.64 and a 200 day moving average price of $70.22. CONMED has a 1 year low of $61.05 and a 1 year high of $88.60.

CONMED (NYSE:CNMD) last issued its earnings results on Wednesday, February 5th. The company reported $1.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.20 by $0.14. CONMED had a return on equity of 13.84% and a net margin of 10.23%. On average, research analysts expect that CONMED will post 4.03 earnings per share for the current year.

CONMED Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, January 3rd. Investors of record on Friday, December 20th were issued a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a yield of 1.17%. The ex-dividend date of this dividend was Friday, December 20th. CONMED’s payout ratio is currently 19.00%.

Analysts Set New Price Targets

Several equities research analysts have weighed in on CNMD shares. Wells Fargo & Company lowered their target price on CONMED from $74.00 to $70.00 and set an “equal weight” rating for the company in a report on Thursday. StockNews.com cut shares of CONMED from a “buy” rating to a “hold” rating in a research note on Friday, November 8th. JPMorgan Chase & Co. lowered shares of CONMED from an “overweight” rating to a “neutral” rating and cut their target price for the company from $85.00 to $70.00 in a report on Thursday. Finally, Needham & Company LLC cut their target price on shares of CONMED from $97.00 to $91.00 and set a “buy” rating for the company in a report on Thursday. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, CONMED has an average rating of “Moderate Buy” and a consensus price target of $77.40.

About CONMED

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries.